Botanix Pharmaceuticals operates with dual headquarters in the US and Australia to coordinate US regulatory engagement and Australian market obligations, underscoring its strategy to manage FDA interactions while meeting ASX disclosure requirements. The company touts FDA approval for its Sofdra platform and positions itself as commercially proven and platform-enabled, signaling a regulatory milestone that supports its US dermatology focus. In its latest updates, Botanix reported accelerating Sofdra prescriptions, with June 2026 marking a record monthly shipment and Q4 FY26 total prescriptions up 25% year over year, alongside robust net revenue growth driven by a higher gross-to-net yield. The improving GTN yield is attributed to normalization of US health insurance deductibles, enabling stronger revenue translation from increasing volumes. Management also highlighted disciplined cost control and strategic enhancements, including territory reductions, expanded API sourcing, and stronger patent protection to support long-term profitability and financial flexibility. Investors were informed of a significantly improved cash position, a reduced net cash outflow from operations, and an evolving financial profile that supports continued growth in the US dermatology market.